ROCK2 and psoriasis: Rho-associated protein kinases (ROCK-2) inhibitors, such as belumosudil, represent a novel class targeting cytokine regulation and immune signaling pathways, with early evidence suggesting their potential to improve inflammatory conditions for psoriasis and PsA [81].